Abstract: Ceralasertib (AZD6738) is a potent, orally bioavailable small-molecule inhibitor of the Ataxia Telangiectasia and Rad3-related (ATR) kinase, a master regulator of the DNA damage response (DDR) and replication stress pathways. This comprehensive review explores the therapeutic potential of Ceralasertib, focusing on its dual utility in chemoradiotherapy sensitization and biomarker-driven monotherapy. Preclinical and clinical evidence demonstrates that AZD6738 induces synthetic lethality in tumors harboring specific genomic vulnerabilities, such as ATM deficiency, ARID1A alterations, and oncogene-driven replication stress (e.g., MYCN amplification). Furthermore, Ceralasertib exhibits profound synergistic effects when combined with DNA-damaging chemotherapy, ionizing radiation, PARP inhibitors, and immune checkpoint inhibitors. By abrogating cell cycle checkpoints and activating innate immune pathways like cGAS-STING, Ceralasertib represents a promising precision oncology agent for the treatment of various refractory solid tumors.
1. Introduction
The DNA damage response (DDR) system is a complex network of signaling pathways essential for detecting and repairing DNA lesions, thereby maintaining genomic stability [1]. Central to this network are the transducer kinases Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR). While ATM primarily responds to DNA double-strand breaks (DSBs), the ATR pathway is crucial for coordinating the response to replication stress, stabilizing replication forks, and inducing cell cycle arrest [1][4]. Cancer cells frequently exhibit high levels of endogenous replication stress and often harbor defects in the DDR network (such as ATM or p53 mutations), making them highly reliant on the ATR pathway for survival [1][2]. Ceralasertib (AZD6738) has emerged as a first-in-class, orally active, and highly selective ATR inhibitor [2][4]. By targeting this critical vulnerability, AZD6738 is currently being extensively evaluated in early-phase clinical trials both as a monotherapy for biomarker-selected patients and as a sensitizing agent in combination with chemoradiotherapy and immunomodulators [1][3].
2. Pharmacological Activity
Biomarker-Driven Monotherapy: Ceralasertib exhibits potent single-agent activity in tumors with specific genetic defects, exploiting the concept of synthetic lethality. It is particularly effective in ATM-deficient malignancies, including chronic lymphocytic leukemia (CLL), gastric cancer, and non-small cell lung cancer (NSCLC) [1][4]. Additionally, tumors with loss-of-function mutations in the ARID1A chromatin remodeling protein rely heavily on the ATR pathway, rendering them highly sensitive to AZD6738 [1][3]. Oncogene-driven replication stress also serves as a predictive biomarker; for instance, MYCN-amplified neuroblastoma models demonstrate significant in vitro and in vivo sensitivity to single-agent AZD6738 [5].
Chemoradiotherapy Sensitization: AZD6738 significantly potentiates the cytotoxicity of various DNA-damaging agents. Preclinical models show strong synergy between AZD6738 and platinum-based drugs (cisplatin, carboplatin), antimetabolites (gemcitabine, 5-fluorouracil), and topoisomerase inhibitors [1][3][4]. In pancreatic ductal adenocarcinoma (PDAC), AZD6738 enhances the efficacy of gemcitabine and FOLFIRINOX, overcoming chemoresistance [3]. Furthermore, AZD6738 acts as a potent radiosensitizer by preventing radiation-induced cell cycle arrest, leading to enhanced tumor cell killing across multiple cancer cell lines regardless of p53 or BRCA status [3][4].
Combinations with Targeted and Immunotherapies: Ceralasertib is highly synergistic with PARP inhibitors (e.g., olaparib). This combination induces replication catastrophe in both homologous recombination (HR)-deficient and HR-proficient tumors, partly through the stabilization of PARP-DNA complexes [1][3]. Additionally, AZD6738 enhances the efficacy of immune checkpoint inhibitors (e.g., durvalumab) by modulating the tumor microenvironment and increasing tumor immunogenicity [1][4].
3. Molecular Mechanism of Action
Ceralasertib functions by competitively binding to and inhibiting the kinase activity of ATR. Under normal conditions, ATR is activated by single-stranded DNA (ssDNA) coated with replication protein A (RPA) at stalled replication forks. ATR then phosphorylates its downstream effector, Checkpoint Kinase 1 (CHK1), which enforces the G2/M cell cycle checkpoint and stabilizes the replication fork [3][4]. By inhibiting ATR, AZD6738 prevents CHK1 phosphorylation, thereby abrogating the cell cycle checkpoint. This forces cells with unrepaired DNA damage to prematurely enter mitosis, resulting in asymmetric DNA segregation, replication fork collapse, chromosomal fragmentation, and ultimately, cell death via mitotic catastrophe [1][3][4].
Beyond direct cytotoxicity, ATR inhibition by AZD6738 has profound immunological consequences. The induction of genomic instability and micronuclei formation leads to the leakage of cytosolic DNA. This cytosolic DNA is sensed by the cGAS-STING pathway, which triggers a robust type I interferon (IFN) response. This signaling cascade enhances the infiltration and activation of cytotoxic CD8+ T-cells within the tumor microenvironment, providing a mechanistic rationale for combining AZD6738 with anti-PD-1/PD-L1 therapies [1][3].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific chemical functional groups and their structure-activity relationships, it highlights the optimized pharmacological profile of Ceralasertib (AZD6738) as a next-generation ATR inhibitor. AZD6738 was developed to be a highly potent and selective small molecule, demonstrating an in vitro IC50 of 1 nM for ATR kinase activity and an IC50 of 74 nM for the inhibition of downstream CHK1 phosphorylation [4]. Crucially, unlike earlier ATR inhibitors (such as the intravenously administered berzosertib/M6620), AZD6738 is orally bioavailable. This oral route of administration offers significant clinical advantages, avoiding the need for intravenous infusions and allowing for more flexible, continuous, or sequential dosing schedules in combination regimens [2][4].
5. Current Limitations
Despite its promise, the clinical application of Ceralasertib faces several limitations. The primary challenge is overlapping toxicity when combined with other DNA-damaging agents. Dose-limiting toxicities (DLTs) frequently include hematologic adverse events—such as grade 3/4 thrombocytopenia, neutropenia, and anemia—as well as gastrointestinal issues [3][4]. Because ATR is essential for the survival of replicating normal cells, the therapeutic window can be narrow [2].
Furthermore, the success of AZD6738 relies heavily on accurate patient stratification. Unselected patient populations often show limited response rates. Identifying and validating robust predictive biomarkers remains a hurdle; for example, distinguishing between tumors with partial ATM depletion (ATM-low) versus complete loss of function (ATM-null) is critical, as only the latter may exhibit true synthetic lethality with ATR inhibitors [3]. Finally, acquired resistance mechanisms, such as alterations in cell cycle regulation or metabolic pathways, pose ongoing challenges to long-term efficacy [3].
6. Future Perspectives
The future of Ceralasertib lies in refining biomarker-driven patient selection and optimizing combination treatment schedules. Numerous clinical trials (e.g., HUDSON, PATRIOT, OLAPCO, CAPRI, VIOLETTE) are currently evaluating AZD6738 across various solid tumors [1][4]. To mitigate dose-limiting toxicities, researchers are exploring sequential dosing strategies—such as administering AZD6738 prior to a PARP inhibitor—which has shown preclinical promise in overcoming acquired chemoresistance while sparing normal tissues [3].
Additionally, the discovery of novel predictive biomarkers, such as TOPBP1 overexpression, Schlafen 11 (SLFN11) status, and ARID1A mutations, will help tailor therapies to the most susceptible patient populations [1][2][3]. The integration of AZD6738 with immune checkpoint inhibitors (like durvalumab) continues to be a major focus, aiming to convert immunologically "cold" tumors into "hot" tumors via cGAS-STING activation [1]. Finally, novel combinations with agents like GRP78 inhibitors or targeted alpha therapies represent exciting frontiers for expanding the clinical utility of ATR inhibition [3][4].
